Trials / No Longer Available
No Longer AvailableNCT06841874
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Nuvation Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This Expanded Access Program will provide access of taletrectinib therapy to patients with locally advanced or metastatic ROS1-positive NSCLC who are not an appropriate candidate for an approved therapy, for any ongoing taletrectinib clinical trial and who, in the opinion of their oncologist, may benefit from treatment.
Detailed description
This Expanded Access Program will provide access of taletrectinib therapy to patients with locally advanced or metastatic c-ros-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). These patients are not an appropriate candidate for an approved therapy, including crizotinib, entrectinib, or repotrectinib, for participating in ongoing Nuvation Bio clinical trial AB-106-G208 and who, in the opinion of their oncologist, may benefit from treatment.
Conditions
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma
- Bronchogenic Carcinoma
- Non Small Cell Carcinoma of the Lung
- ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Taletrectinib | Oral capsule |
Timeline
- First posted
- 2025-02-24
- Last updated
- 2025-12-24
Source: ClinicalTrials.gov record NCT06841874. Inclusion in this directory is not an endorsement.